T cell receptor-targeted immunotherapeutics drive selective in vivo HIV- And CMV-specific T cell expansion in humanized mice

Keyphrases

• T Cell Receptor 100%
• Receptor Targets 100%
• Immunotherapeutics 100%
• Derived Peptide 100%
• T Cell Expansion 100%
• Humanized Mice 100%
• HIV-specific T Cells 100%
• CMV-specific T Cells 100%
• CMV-specific CD8+ T Cells 100%
• Costimulatory Signal 100%
• HIV Infection 50%
• Therapeutic Strategies 50%
• T Cell Activation 50%
• Antigen-presenting Cells 50%
• CD28 50%
• Spleen 50%
• Intravenous Injection 50%
• In Vivo Role 50%
• HLA-A2 50%
• Viral Infection 50%
• Virus-specific 50%
• Immunodeficient Mice 50%
• 4-1BB 50%
• In Vivo Effects 50%
• Antigen-specific T Cells 50%
• Cytotoxic CD8+ T Cells 50%
• Antiviral Activity 50%
• MHC Molecules 50%
• Human CD8+ T Cells 50%
• Ex Vivo Expansion 50%
• CMV Infection 50%
• HIV Cure 50%
• Fc Domain 50%
• Virus-specific CD8+ T Cells 50%
• HIV-infected Donors 50%
• Patient-derived 50%
• Specific Ligand 50%
• Individualized Therapy 50%

Immunology and Microbiology

• Human Immunodeficiency Virus 100%
• T Cell 100%
• T Cell Receptor 100%
• Cell Expansion 100%
• Humanized Mouse 100%
• Cytotoxic T-Cell 45%
• Virus 18%
• Peptides 18%
• Antigen-Presenting Cell 9%
• T Cell Activation 9%
• CD28 9%
• Antigen Specificity 9%
• Biological Product 9%
• Viral Disease 9%
• Infectious Disease 9%
• Antiviral Activity 9%
• Infection 9%